Diurnal seeks marketing authorisation for Chronocort in the UK
MHRA submission is based on same application filed with the EMA
Read More
Tag: Chronocort
EMA confirms path for Diurnal’s Chronocort despite trial failure
The company is on track to submit a Marketing Authorisation Application in the fourth quarter of 2019.
Read More
Diurnal shares plummet on trial failure
Shares in UK speciality pharma Diurnal plummeted more than 50 percent on news that a late-stage study of an experimental treatment for congenital adrenal hyperplasia (CAH) failed to meet its primary objective.
Read More
- MHRA approves new treatment for severe alopecia areata
- Aplagon doses first patient in phase 2a trial of APAC
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
- UCB reports superiority of bimekizumab in psoriatic arthritis study
- Kainova reports positive results for DT‑9081 in advanced solid tumours
